MAIA Biotechnology Files 8-K
Ticker: MAIA · Form: 8-K · Filed: Jun 6, 2024 · CIK: 1878313
| Field | Detail |
|---|---|
| Company | Maia Biotechnology, INC. (MAIA) |
| Form Type | 8-K |
| Filed Date | Jun 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, SEC filing
TL;DR
MAIA Bio filed an 8-K, likely routine updates, no major news yet.
AI Summary
MAIA Biotechnology, Inc. filed an 8-K on June 6, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the reporting of these items.
Why It Matters
This filing indicates MAIA Biotechnology is providing updates or disclosures required by the SEC, which could relate to ongoing business operations or financial reporting.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for disclosures and exhibits, not indicating any immediate negative or positive material events.
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Registrant
- June 6, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Chicago, IL (location) — Principal executive offices address
FAQ
What is the primary purpose of this 8-K filing for MAIA Biotechnology, Inc.?
The primary purpose of this 8-K filing is to report on a Regulation FD Disclosure and Financial Statements and Exhibits.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on June 6, 2024.
In which state is MAIA Biotechnology, Inc. incorporated?
MAIA Biotechnology, Inc. is incorporated in Delaware.
What is the principal executive office address for MAIA Biotechnology, Inc.?
The principal executive office address is 444 West Lake Street, Suite 1700, Chicago, IL 60606.
Does this 8-K filing disclose any specific financial results or material events?
This filing does not appear to disclose specific financial results or material events beyond the reporting of required disclosures and exhibits.
Filing Stats: 513 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-06-06 14:57:40
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex99-1.htm (EX-99.1) — 27KB
- 0001493152-24-022906.txt ( ) — 244KB
- maia-20240606.xsd (EX-101.SCH) — 3KB
- maia-20240606_lab.xml (EX-101.LAB) — 33KB
- maia-20240606_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 6, 2024 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 3